Development of hybrid viral vectors for gene therapy.
Adenoviral, retroviral/lentiviral, adeno-associated viral, and herpesviral vectors are the major viral vectors used in gene therapy. Compared with non-viral methods, viruses are highly-evolved, natural delivery agents for genetic materials. Despite their remarkable transduction efficiency, both clinical trials and laboratory experiments have suggested that viral vectors have inherent shortcomings for gene therapy, including limited loading capacity, immunogenicity, genotoxicity, and failure to support long-term adequate transgenic expression. One of the key issues in viral gene therapy is the state of the delivered genetic material in transduced cells. To address genotoxicity and improve the therapeutic transgene expression profile, construction of hybrid vectors have recently been developed. By adding new abilities or replacing certain undesirable elements, novel hybrid viral vectors are expected to outperform their conventional counterparts with improved safety and enhanced therapeutic efficacy. This review provides a comprehensive summary of current achievements in hybrid viral vector development and their impact on the field of gene therapy.
Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.
Shuohao
S
Huang
Masamichi
M
Kamihira
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002678:Chimera; D004251:DNA Transposable Elements; D005786:Gene Expression Regulation; D005818:Genetic Engineering / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000494:pharmacology*; D006564:Herpesviridae / Q000235:genetics*; D059765:Homologous Recombination; D006801:Humans; D012190:Retroviridae / Q000235:genetics*; D019076:Transgenes; D014764:Viral Proteins / Q000235:genetics
D004251:DNA Transposable Elements; D014764:Viral Proteins